1C
APLS

111 Capital’s Apellis Pharmaceuticals APLS Stock Holding History

111 Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,400
Closed -$215K – 458
2025
Q2 		$215K Sell
12,400
-4,436
-26% -$82.1K 0.04% 439
2025
Q1 		$368K Buy
+16,836
New +$465K 0.07% 280

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

111 Capital's APLS Position: Q3 2025 in Review

111 Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 12,400 shares — an estimated $215K sold.

111 Capital first reported a position in APLS in Q1 2025 and held it in 2 quarters. The position peaked at $368K in Q1 2025. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • 111 Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • 111 Capital sold 12,400 Apellis Pharmaceuticals shares in Q3 2025, an estimated $215K.
  • 111 Capital first reported a position in Apellis Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • 111 Capital's Apellis Pharmaceuticals position peaked at $368K in Q1 2025.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.